Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Clinical Characteristics, Treatment and Outcomes of Patients with Paraneoplastic Neuropathies. A Retrospective Single-Center Study in Argentina.
Neuromuscular and Clinical Neurophysiology (EMG)
P14 - Poster Session 14 (11:45 AM-12:45 PM)
Peripheral neuropathy represents one of the most common presentations of paraneoplastic neurological disorders. Being a rare entity, clinical suspicion is extremely important.
To describe the clinical features, treatments and outcomes in patients diagnosed with Paraneoplastic Neuropathies (PN).
Medical records of PN patients between 2010 and 2021 were reviewed.
Nineteen patients were included, 68% (13/19) were women, and the mean age at symptom onset was 56.26 years (SD 11.9). In most cases (73.7%) the onset of symptoms was subacute (2 weeks to 3 months). Paresthesias (9/19) and pain (5/19) were the most frequent symptoms. Sensorimotor neuropathy was the most frequent phenotype (8/19). An onconeural antibody was identified in 14 patients (73.7%).  Primary tumors were found in 9 patients (47.3%). Lung cancer was the most frequent tumor (33.3%).

The latency between PN and the diagnosis of tumors was 27.9 months (SD 18.18). Twelve patients (63.2%) were treated with immunotherapy. In two cases a clinically significant improvement was evidenced (10.5%), 68.4% of patients (13/19) remained stable, 4 patients worsened their symptoms (21%) and three patients died (15%).

Sensory complaints and a subacute presentation were the most frequent in the majority of cases. The most common phenotype is sensorimotor neuropathy, so this entity should be suspected in patients with these characteristics after proper exclusion of other more frequent causes.

Francisco Caiza Zambrano (Hospital Británico de Buenos Aires)
Mr. Caiza Zambrano has nothing to disclose.
Fabio Gonzalez Fabio Gonzalez has nothing to disclose.
Julio Cesar Galarza Menoscal, PhD (Hospital Britanico de Buenos Aires) Dr. Galarza Menoscal has nothing to disclose.
Mauricio Benetti, Sr., PhD (Hospital Británico) Dr. Benetti has nothing to disclose.
Marcela Uribe Roca (Hospital De Clinicas) The institution of Marcela Uribe Roca has received research support from Roche.
Pablo Bonardo, MD Dr. Bonardo has nothing to disclose.
Manuel Fernandez Pardal Manuel Fernandez Pardal has nothing to disclose.
Luciana Vanesa Leon Cejas, MD (Hospital Britanico) Dr. Leon Cejas has nothing to disclose.
Ricardo C. Reisin, MD (Hospital Britanico) Dr. Reisin has nothing to disclose.